Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06954522 Safety and PK Study in T2DM and Obesity
NCT06279234Phase 1Completed
- Sponsor
- Pfizer
- Start
- Feb 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06954522 in type 2 diabetes mellitus (T2DM) and obesity (5 arms), sponsored by Pfizer. Primary endpoints: Number of Participants Reporting Adverse Events, Number of Participants with Clinically Significant Change From Baseline in Laboratory Abnormalities and 3 more. Started Feb 2024; status: completed.
02
Drugs
PF-06954522
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06279234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06279234.